There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
When your investment case breaks down, why not just do the decent thing?
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
The players are vying in the CD19 x CD20 Car-T arena.
